Related Experiment Videos

PRAME expression and clinical outcome of breast cancer

M T Epping1, A A M Hart, A M Glas

  • 1Division of Molecular Carcinogenesis and Centre for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.

British Journal of Cancer
|July 24, 2008
PubMed

Insights

High PReferentially expressed Antigen of MElanoma (PRAME) gene expression in breast cancer patients correlates with increased metastasis and decreased survival. PRAME serves as an independent prognostic marker for breast cancer outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The tumor antigen PReferentially expressed Antigen of MElanoma (PRAME) is implicated in various cancers.
  • PRAME expression has been observed in breast cancer tissues.

Purpose of the Study:

  • To investigate the correlation between PRAME gene expression and clinical outcomes in primary breast cancer patients.
  • To determine if PRAME expression is an independent prognostic marker for breast cancer patients.

Main Methods:

  • Analysis of PRAME gene expression in 295 primary breast cancer patients.
  • Kaplan-Meier survival analysis to assess the relationship between PRAME levels and survival rates.
  • Multivariable analysis to evaluate PRAME as an independent prognostic factor.

Main Results:

  • Elevated PRAME expression correlated with higher rates of distant metastases.
  • Increased PRAME levels were associated with decreased overall patient survival.
  • PRAME was an independent predictor of a shortened metastasis-free interval, particularly in patients not receiving adjuvant chemotherapy.
  • PRAME expression was linked to higher tumor grade and negative estrogen receptor status.

Conclusions:

  • PRAME gene expression is a significant prognostic marker for breast cancer patient outcomes.
  • PRAME provides prognostic information independent of established clinicopathological markers.
  • PRAME warrants further investigation as a potential therapeutic target or biomarker in breast cancer management.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...